Nicholas Thomas

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Jienchi Dorward, Ly‐Mee Yu et al. · The Lancet · 2021 · 318 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al. · The Lancet · 2021 · 310 citations · Full text

Pharmacy, Community Medicine, Pharmacotherapy +14

Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England

Simon de Lusignan, Jamie Lopez Bernal, Maria Zambon et al. · JMIR Public Health and Surveillance · 2020 · 87 citations · Full text

Public Health, Infectious Diseases, Public Health Practice +17

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Christopher Butler, Ly‐Mee Yu, Jienchi Dorward et al. · The Lancet Respiratory Medicine · 2021 · 84 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +9